These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24627483)

  • 1. Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.
    Vangala JR; Dudem S; Jain N; Kalivendi SV
    J Biol Chem; 2014 May; 289(18):12612-22. PubMed ID: 24627483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
    Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
    Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
    Yang YM; Lee S; Nam CW; Ha JH; Jayaraman M; Dhanasekaran DN; Lee CH; Kwak MK; Kim SG
    Carcinogenesis; 2010 Jul; 31(7):1230-7. PubMed ID: 20478922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
    Lü S; Chen Z; Yang J; Chen L; Gong S; Zhou H; Guo L; Wang J
    Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
    Oerlemans R; Franke NE; Assaraf YG; Cloos J; van Zantwijk I; Berkers CR; Scheffer GL; Debipersad K; Vojtekova K; Lemos C; van der Heijden JW; Ylstra B; Peters GJ; Kaspers GL; Dijkmans BA; Scheper RJ; Jansen G
    Blood; 2008 Sep; 112(6):2489-99. PubMed ID: 18565852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
    Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
    Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation.
    Jin S; Li B; Zhang B; Gao X; Jia X; Xu L; Chang S; Hu K; Wang G; Xu Z; Zhang T; Song D; Yang G; Wu X; Zhu H; Huang C; Lu Y; Shi J; Zhu W; Chen G
    Acta Biochim Biophys Sin (Shanghai); 2023 Dec; 55(12):1884-1891. PubMed ID: 38009004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib up-regulates activated signal transducer and activator of transcription-3 and synergizes with inhibitors of signal transducer and activator of transcription-3 to promote head and neck squamous cell carcinoma cell death.
    Li C; Zang Y; Sen M; Leeman-Neill RJ; Man DS; Grandis JR; Johnson DE
    Mol Cancer Ther; 2009 Aug; 8(8):2211-20. PubMed ID: 19638453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
    Ri M; Iida S; Nakashima T; Miyazaki H; Mori F; Ito A; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Shiotsu Y; Ueda R
    Leukemia; 2010 Aug; 24(8):1506-12. PubMed ID: 20555361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apigenin manipulates the ubiquitin-proteasome system to rescue estrogen receptor-β from degradation and induce apoptosis in prostate cancer cells.
    Singh V; Sharma V; Verma V; Pandey D; Yadav SK; Maikhuri JP; Gupta G
    Eur J Nutr; 2015 Dec; 54(8):1255-67. PubMed ID: 25408199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.
    Zhang XD; Baladandayuthapani V; Lin H; Mulligan G; Li B; Esseltine DW; Qi L; Xu J; Hunziker W; Barlogie B; Usmani SZ; Zhang Q; Crowley J; Hoering A; Shah JJ; Weber DM; Manasanch EE; Thomas SK; Li BZ; Wang HH; Zhang J; Kuiatse I; Tang JL; Wang H; He J; Yang J; Milan E; Cenci S; Ma WC; Wang ZQ; Davis RE; Yang L; Orlowski RZ
    Cancer Cell; 2016 May; 29(5):639-652. PubMed ID: 27132469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.
    Lü S; Yang J; Chen Z; Gong S; Zhou H; Xu X; Wang J
    Exp Hematol; 2009 Jul; 37(7):831-7. PubMed ID: 19426847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutive and B-cell receptor-induced activation of STAT3 are important signaling pathways targeted by bortezomib in leukemic mantle cell lymphoma.
    Baran-Marszak F; Boukhiar M; Harel S; Laguillier C; Roger C; Gressin R; Martin A; Fagard R; Varin-Blank N; Ajchenbaum-Cymbalista F; Ledoux D
    Haematologica; 2010 Nov; 95(11):1865-72. PubMed ID: 20663948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
    Kim JE; Jin DH; Lee WJ; Hur D; Wu TC; Kim D
    Pharmacol Res; 2013 May; 71():23-33. PubMed ID: 23428347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
    Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
    [No Abstract]   [Full Text] [Related]  

  • 17. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
    Lü S; Yang J; Song X; Gong S; Zhou H; Guo L; Song N; Bao X; Chen P; Wang J
    J Pharmacol Exp Ther; 2008 Aug; 326(2):423-31. PubMed ID: 18502982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
    Lichter DI; Danaee H; Pickard MD; Tayber O; Sintchak M; Shi H; Richardson PG; Cavenagh J; Bladé J; Façon T; Niesvizky R; Alsina M; Dalton W; Sonneveld P; Lonial S; van de Velde H; Ricci D; Esseltine DL; Trepicchio WL; Mulligan G; Anderson KC
    Blood; 2012 Nov; 120(23):4513-6. PubMed ID: 23018640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-383 sensitizes osteosarcoma cells to bortezomib treatment via down-regulating PSMB5.
    Wang H; Bai C; Dang X; Wang H
    Mol Biol Rep; 2024 Jan; 51(1):170. PubMed ID: 38252234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.